Additionally, the subgroup analysis from the CLARINET trial showed no difference in the therapeutic effects of lanreotide on PFS according to age (≤65 years vs. >65 years) while sex, age, ethnicity, geographical region, time since diagnosis, Ki67 percentage, tumor grade, chromogranin A level, prior chemotherapy and prior surgery were not associated with PFS. The gene discussed is MKI67; the disease is neoplasm.